Jagsonpal Pharmaceuticals is trading at ₹241.48 (+7.02%) amid its announced wellness-portfolio acquisition, the clearest company-specific catalyst for the September 24 rally; causation is unconfirmed.
- On September 23, 2026, the company announced a slump sale agreement to acquire Group Pharmaceuticals’ wellness portfolio for up to ₹46.7 crore: ₹23.7 crore at closing and up to ₹23.0 crore linked to FY28 sales.
- Completion is expected by November 1, 2026.